Home

 What is Hepatitis

 How is it Transmitted

 Long Term Prognosis

 Complications of HCV

 Liver Biopsy

 Treatment Info (Interferon, Herbal, etc)

 Lab Tests (PCR, Genotype,etc.)

 Nutrition & Alternative Info

 Patient Information (Support Groups, Doctor Listing, etc)

 Related Webpages

 Transplant Info

 Site Search

 HCV Webrings

 My guestbookbook

 Site Awards

 FAQ & Disclaimers


Influence of genotype & level of viremia on the severity of liver injury and reponse to Inteferon

Background:
We wanted to investigate the influence of viral genotype on the severity of liver injury and response to interferon and whether the level of viremia differs in accordance with genotype, severity of liver disease, and response to interferon in patients with hepatitis C virus (HCV) infection.

Methods:
We studied 118 patients with HCV-related liver disease. HCV genotypes were determined with a line probe assay, and serum HCV RNA levels with a competitive reverse transcription polymerase chain reaction assay.

Results:
HCV type Ib was the most prevalent genotype (88%). It was present in 100% of cirrhotic patients, with or without hepatocellular carcinoma (HCC), but only in 78% of patients with chronic hepatitis (P <0.001). The response to interferon was better in patients infected with non-lb HCV genotypes (P = 0.002). In a multivariate analysis non-lb HCV genotypes and a low hepatic fibrosis correlated with a favorable response to interferon. Among patients with chronic hepatitis those infected with HCV type Ib were older (P < 0.001), and age was the only independent factor associated with HCV type Ib. Viremia levels differed neither between genotypes nor in response to interferon and was significantly lower in patients with cirrhosis and HCC.

Conclusions:
HCV 1b was associated with more severe liver disease and a worse response to interferon therapy. Non-lb genotypes and a lower liver fibrosis were the only independent predictors of a favorable response to interferon. Levels of HCV viremia differed neither among different genotypes nor in response to interferon and decreased with advanced liver disease.

Author: FERNANDEZ I, HOSP 12 OCTUBRE, SERV APARATO DIGEST, CTRA ANDAULUCIA KM 54, E-28041 MADRID, SPAIN
Source: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 1997 JAN;32(1):70-76


Home | What is HCV | Transmission | Future | Complications | Biopsy | Treatment | Lab | Nutrition | Patient | Links | Transplant | Webrings | guestbookbook | Awards | FAQ |